Compare Quest Diagnostics Inc (DGX) vs Grab Holdings Ltd. (GRAB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Grab Holdings Ltd. — how do they compare? Quest Diagnostics Inc trades at $237.98 (market cap $26.21B), while Grab Holdings Ltd. trades at $3.62 (market cap $15.26B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Grab Holdings Ltd. pays none. Which is the better fit depends on your goals.
| DGX | GRAB | |
|---|---|---|
Market Cap | $26.21B | $15.26B |
Sector | Health | Technology |
52-Week High | $238.50 | $6.45 |
52-Week Low | $173.49 | $3.27 |
Enterprise Value | $31.97B | $10.99B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
GRAB trades at $3.625, down 1.23% on the day, showing strong fundamental momentum with three consecutive quarterly earnings beats and a significant turnaround to profitability. The company reported Q2 2026 EPS of $0.06 versus $0.05 expected, with revenue growth accelerating to $3.37 billion in 2025. Technical indicators show a bullish trend with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions near-term.
GRAB presents a compelling growth story with improving profitability and strong analyst support (91.67% buy ratings). The company's raised 2026 guidance and expanding super app ecosystem signal continued momentum. Key risks include volatile cash flow patterns, competitive pressures in Southeast Asia, and recent insider selling activity that warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →
